文献速递白血病

ENESTfreedom 研究5年更新:一线尼洛替尼治疗后无治疗缓解

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
PubMed 文献 · Leukemia · 2021-03-11

ENESTfreedom 试验评估慢性期慢性髓性白血病(CML-CP)患者接受一线尼洛替尼治疗达到 MR4.5 后尝试无治疗缓解(TFR)的可行性。5年随访时,进入 TFR 期的190例患者中81例(42.6%)仍处于 TFR,76例(40.0%)维持 MR4.5;失去主要分子学反应(MMR)后重新治疗的患者中98.9%重获 MMR、92.3%重获 MR4.5。5年无治疗生存率估计为48.2%,未报告疾病进展或 CML 相关死亡。

要点

  • 一线尼洛替尼治疗≥2年且达 MR4.5 并巩固1年后,5年 TFR 率42.6%。
  • TFR 期失去 MMR 后重新治疗,98.9%重获 MMR、92.3%重获 MR4.5。
  • 低 Sokal 评分、TFR 48周时 BCR-ABL1IS 水平及首年稳定 MR4.5 与更高 TFR 率相关。

核心结论

  • CML-CP 患者接受一线尼洛替尼治疗>3年并达到 MR4.5 后尝试 TFR 具有疗效和安全性支持。

研究设计与样本

  • ENESTfreedom 试验:接受≥2年一线尼洛替尼治疗且达 MR4.5 的患者,经1年尼洛替尼巩固后进入 TFR 期。
  • 5年数据截止时,进入 TFR 期患者共190例。

主要发现

  • 81/190例(42.6%)仍处于 TFR,其中76例(40.0%)维持 MR4.5。
  • 进入重新治疗期的91例中,90例(98.9%)重获 MMR,84例(92.3%)重获 MR4.5。
  • 5年无治疗生存率 Kaplan-Meier 估计为48.2%。
  • 未报告疾病进展或 CML 相关死亡。
  • TFR 开始后96周起不良事件(AE)发生率下降,但重新治疗期 AE 频率增加。

关键数值与推荐

  • 低 Sokal 风险评分、TFR 48周时 BCR-ABL1IS 水平及 TFR 首年稳定 MR4.5 反应与更高 TFR 率相关。

临床怎么用

  • 支持对一线尼洛替尼治疗>3年且达 MR4.5 的 CML-CP 患者尝试 TFR,并需监测 MMR 丢失后重新治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib treatment. Results for long-term outcomes after a 5-year follow-up are presented herein. Patients who had received ≥2 years of frontline nilotinib therapy and achieved MR4.5 underwent a 1-year nilotinib treatment consolidation phase before attempting TFR. At the 5-year data cut-off, 81/190 patients entering the TFR phase (42.6%) were still in TFR, with 76 (40.0%) in MR4.5. Patients who lost major molecular response (MMR) entered a treatment re-initiation phase; 90/91 patients entering this phase (98.9%) regained MMR and 84/91 patients (92.3%) regained MR4.5. The Kaplan-Meier estimated treatment-free survival rate at 5 years was 48.2%. No disease progression or CML-related deaths were reported. Whereas the incidence of adverse events (AEs) declined from 96 weeks following the start of TFR, an increase in AE frequency was observed for patients in the treatment re-initiation phase. Low Sokal risk score, BCR-ABL1IS levels at 48 weeks of TFR and stable MR4.5 response for the first year of TFR were associated with higher TFR rates. Overall, these results support the efficacy and safety of attempting TFR following upfront nilotinib therapy of >3 years in patients with CML-CP.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021. PMID: 33707652. doi:10.1038/s41375-021-01205-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。